Find an MSK Doctor or Cancer Specialist
Memorial Sloan Kettering medical oncologist Yelena Janjigian

Yelena Y. Janjigian, MD

Gastrointestinal Medical Oncologist

Areas of Expertise

Conditions I Treat

  • Gastrointestinal cancers and conditions
  • Esophageal cancers and conditions
  • Stomach (gastric) cancer

My Specialties

  • Chemotherapy
View all
Dr. Janjigian's Office Information
Languages: English
Request an Appointment
Our Care Advisors can answer many of your questions. They will connect you with the best healthcare provider for your needs.
Back to top
Share

Get to Know Me

I am a medical oncologist who cares for people with cancers of the gastrointestinal (GI) tract. My clinical practice and research are focused on improving outcomes for people with esophageal and stomach cancers.

When patients first meet with me, they are often scared and have many questions. They usually want to know about their treatment options, chances for survival, and how their quality of life will be affected. I take the time to answer their questions clearly and honestly. My goal is to work with them to create the best possible care plan for their specific needs and preferences. I want my patients to leave our consultation feeling confident that they are in good hands.

As Chief of the Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center (MSK), I lead a dedicated team of experienced and compassionate physicians. My mission is to encourage research and the development of new therapies to help patients worldwide.

What I Do at MSK

I'm a gastrointestinal (GAS-troh-in-TES-tih-nul) medical oncologist, which is a cancer doctor who specializes in gastrointestinal (GI) cancers. This includes anal, colorectal, esophageal, gastric (stomach), liver, and pancreatic cancers. We also treat GI stromal tumors and neuroendocrine tumors.

  • Chief, Gastrointestinal Oncology Service
Areas of Expertise

Conditions I Treat

  • Gastrointestinal cancers and conditions
  • Esophageal cancers and conditions
  • Stomach (gastric) cancer

My Specialties

  • Chemotherapy
Education & Honors

Education

  • MD, New York University School of Medicine

Residencies

  • Internal Medicine - New York University School of Medicine/Bellevue Hospital

Fellowships

  • Hematology/Oncology - Memorial Sloan Kettering Cancer Center

Board Certifications

  • Internal Medicine
  • Medical Oncology

Insurance Information

Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.

Aetna

In Network Coverage Type
HMO, EPO PPO, POS, Transplant

Aetna Medicare Advantage (MTA and NYC retirees only)

In Network Coverage Type
PPO

Anthem BCBS and other BCBS licensee plans

In Network Coverage Type
PPO, POS, EPO, HMO

See updates

Anthem BCBS Health Plus

In Network Coverage Type
HMO

See updates

Horizon Medicare Advantage

In Network Coverage Type
PPO, HMO

Healthfirst Medicare Advantage

In Network Coverage Type
HMO, PPO

Fidelis Medicare Advantage

In Network Coverage Type
HMO

Blue Cross Blue Shield Federal Employee Program

In Network Coverage Type
HMO, PPO

See updates

Blue Cross Blue Shield states outside of NY/NJ

In Network Coverage Type
HMO, EPO PPO, POS

See updates

Carrum Health

In Network Coverage Type
Supplemental

Cigna

In Network Coverage Type
PPO, POS, HMO

Connecticare

In Network Coverage Type
POS, EPO, HMO

Straight NJ Medicaid

In Network Coverage Type
State Government

Straight NY Medicaid

In Network Coverage Type
State Government

Emblem

In Network Coverage Type
PPO, POS, EPO, HMO

Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.

Emblem Essential

In Network Coverage Type
HMO

Emblem Medicare Advantage (Medicare Choice PPO Network and VIP Prime Network Only)

In Network Coverage Type
PPO, HMO

Empire Essential

In Network Coverage Type
HMO

Empire Plan / NYSHIP (Blue Cross/UnitedHealthcare split plan)

In Network Coverage Type
PPO

See updates

Fidelis

In Network Coverage Type
HMO, EPO

Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.

Fidelis Managed Medicaid & HARP

In Network Coverage Type
HMO

First Health

In Network Coverage Type
PPO

Husky CT Medicaid

In Network Coverage Type
State Government

Healthfirst

In Network Coverage Type
EPO, HMO, PPO, POS

Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.

Healthfirst Managed Medicaid

In Network Coverage Type
HMO

Healthsmart

In Network Coverage Type
PPO EPO

Horizon Blue Cross Blue Shield New Jersey (HMO)

In Network Coverage Type
HMO

See updates

Horizon Blue Cross Blue Shield New Jersey (PPO)

In Network Coverage Type
PPO

See updates

Horizon Blue Cross Blue Shield New Jersey Omnia Tier I (EPO)

In Network Coverage Type
EPO

See updates

Horizon Blue Cross Blue Shield New Jersey Omnia Tier II (EPO)

In Network Coverage Type
EPO

See updates

NYC Medicare Advantage Plus for City Employees

In Network Coverage Type
TBD

Magnacare

In Network Coverage Type
PPO, POS, EPO

Medicare Part A&B (traditional Medicare)

In Network Coverage Type
Federal Government

Metroplus

In Network Coverage Type
HMO

City Employee Health Plans (Gold and Gold Care)

Multiplan/Beech Street/PHCS

In Network Coverage Type
Supplemental

MVP

In Network Coverage Type
PPO/OAP

Non-Participating Plans with Out of Network Benefits

In Network Coverage Type
PPO, POS, EPO, HMO

Oscar

In Network Coverage Type
HMO/EPO

Oxford

In Network Coverage Type
PPO, EPO

World Trade Center Health Program (WTC)

In Network Coverage Type
State Government

Qualcare

In Network Coverage Type
PPO, POS, HMO

Tricare

In Network Coverage Type
PPO, HMO

UMR

In Network Coverage Type
PPO, POS

United Healthcare

In Network Coverage Type
PPO, POS, HMO

Don't see your carrier or plan? We can help you understand your coverage.

If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.

If you have questions about insurance, call us at 646-497-9176.

Make an Appointment

Women talking
New Patients
Scheduling an appointment is easy. Click or call 646-497-9053— we’re available 24 hours a day, 7 days a week
Make an Appointment
Current Patients
Request an appointment by logging in to MSK MyChart or calling your Care Team. If you are not enrolled in MSK MyChart, ask your Care Team to send you an invitation. You can also go to MSK MyChart and select “Sign up now.”

Contact and Location

Dr. Janjigian sees patients at one location.

Office Phone
Location
New York, NY
Rockefeller Outpatient Pavilion
160 East 53rd Street New York NY 10022
Get Directions

Looking to see a doctor at a different location? See all MSK locations.

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

See all Gastrointestinal Oncology Service doctors

Clinical Trials

Read more
Smiling doctors in the lab
Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Search clinical trials

Research and Publications

Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li M, Ajani JA. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021 Jul 3;398(10294):27-40. doi: 10.1016/S0140-6736(21)00797-2. Epub 2021 Jun 5. PMID: 34102137; PMCID: PMC8436782.


Janjigian YY, Kawazoe A, Yañez P, Li N, Lonardi S, Kolesnik O, Barajas O, Bai Y, Shen L, Tang Y, Wyrwicz LS, Xu J, Shitara K, Qin S, Van Cutsem E, Tabernero J, Li L, Shah S, Bhagia P, Chung HC. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021 Dec;600(7890):727-730. doi: 10.1038/s41586-021-04161-3. Epub 2021 Dec 15. PMID: 34912120; PMCID: PMC8959470.

Shitara K, Ajani JA, Moehler M, Garrido M, Gallardo C, Shen L, Yamaguchi K, Wyrwicz L, Skoczylas T, Bragagnoli AC, Liu T, Tehfe M, Elimova E, Bruges R, Zander T, de Azevedo S, Kowalyszyn R, Pazo-Cid R, Schenker M, Cleary JM, Yanez P, Feeney K, Karamouzis MV, Poulart V, Lei M, Xiao H, Kondo K, Li M, Janjigian YY. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022 Mar;603(7903):942-948. doi: 10.1038/s41586-022-04508-4. Epub 2022 Mar 23. PMID: 35322232; PMCID: PMC8967713.
 
Read more
 
Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, Ross DS, Hechtman JF, DeLair DF, Yao J, Mandelker DL, Cheng DT, Chandramohan R, Mohanty AS, Ptashkin RN, Jayakumaran G, Prasad M, Syed MH, Rema AB, Liu ZY, Nafa K, Borsu L, Sadowska J, Casanova J, Bacares R, Kiecka IJ, Razumova A, Son JB, Stewart L, Baldi T, Mullaney KA, Al-Ahmadie H, Vakiani E, Abeshouse AA, Penson AV, Jonsson P, Camacho N, Chang MT, Won HH, Gross BE, Kundra R, Heins ZJ, Chen HW, Phillips S, Zhang H, Wang J, Ochoa A, Wills J, Eubank M, Thomas SB, Gardos SM, Reales DN, Galle J, Durany R, Cambria R, Abida W, Cercek A, Feldman DR, Gounder MM, Hakimi AA, Harding JJ, Iyer G, Janjigian YY, Jordan EJ, Kelly CM, Lowery MA, Morris LGT, Omuro AM, Raj N, Razavi P, Shoushtari AN, Shukla N, Soumerai TE, Varghese AM, Yaeger R, Coleman J, Bochner B, Riely GJ, Saltz LB, Scher HI, Sabbatini PJ, Robson ME, Klimstra DS, Taylor BS, Baselga J, Schultz N, Hyman DM, Arcila ME, Solit DB, Ladanyi M, Berger MF. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017 Jun;23(6):703-713. doi: 10.1038/nm.4333. Epub 2017 May 8. Erratum in: Nat Med. 2017 Aug 4;23 (8):1004. PMID: 28481359; PMCID: PMC5461196.
Publications on PubMed

Visit PubMed for a full listing of Dr. Janjigian’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.

See all on PubMed

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Yelena Y. Janjigian discloses the following relationships and financial interests:

  • American Association for Cancer Research
    Professional Services and Activities (Uncompensated)
  • American Society of Clinical Oncology (ASCO)
    Professional Services and Activities
  • Arcus Biosciences, Inc.
    Professional Services and Activities (Uncompensated)
  • AskGene Pharma, Inc.
    Professional Services and Activities
  • AstraZeneca
    Professional Services and Activities
  • Bayer
    Professional Services and Activities
  • Boehringer Ingelheim
    Professional Services and Activities (Uncompensated)
  • Bristol-Myers Squibb
    Professional Services and Activities
  • Chinese American Hematology and Oncology Network
    Professional Services and Activities
  • Clinical Education Alliance, LLC
    Professional Services and Activities
  • COR2ED GmbH
    Professional Services and Activities
  • Creative Educational Concepts, Inc.
    Professional Services and Activities
  • Curio Science LLC
    Professional Services and Activities
  • Daiichi Sankyo
    Professional Services and Activities
  • ED Medresources Inc
    Professional Services and Activities
  • Eisai
    Professional Services and Activities
  • Emory University
    Professional Services and Activities
  • Fundación Santa Fe de Bogotá
    Professional Services and Activities
  • GlaxoSmithKline
    Professional Services and Activities (Uncompensated)
  • Guardant Health, Inc.
    Professional Services and Activities
  • H.C. Wainwright & Co., LLC
    Professional Services and Activities
  • Hospital Sirio-Libanes
    Professional Services and Activities
  • Imedex, Inc.
    Professional Services and Activities
  • Inspirna, Inc.
    Equity
  • Japan Convention Services, Inc.
    Professional Services and Activities
  • Merck & Co Inc.
    Professional Services and Activities
  • MJH Life Sciences
    Professional Services and Activities
  • Netherlands Cancer Institute
    Professional Services and Activities
  • PeerView Institute for Medical Education (PVI)
    Professional Services and Activities
  • PlayToKnow AG
    Professional Services and Activities
  • Research to Practice
    Professional Services and Activities
  • Sanofi S.A.
    Professional Services and Activities
  • Sociedade Brasileira de Oncologia Clínica
    Professional Services and Activities
  • Talem Health, LLC
    Professional Services and Activities
  • Total CME
    Professional Services and Activities
  • Transcenta Holding Limited
    Professional Services and Activities
  • Webinars.Inc
    Professional Services and Activities

If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures

Related topics: